Omega Diagnostics (CNSL) AI Stock Analysis

• Market Cap: £4.64M
• Dividend Yield: N/A
• Average Volume (3M): 353.57K
• Price to Earnings (P/E): 3.4
• Beta (1Y): 1.11
• Revenue Growth: -10.20%
• EPS Growth: 714.29%
• Country: UK
• Employees: 94
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.00
• Shares Outstanding: 237,950,650
• 10 Day Avg. Volume: 111,535
• 30 Day Avg. Volume: 353,573
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.87
• P/FCF Ratio: -51.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: 2.00p ▲(2.56% Upside)

The overall stock score is primarily influenced by the mixed financial performance and bearish technical indicators. While the valuation suggests the stock may be undervalued, significant financial and technical challenges weigh heavily on the score. The positive sentiment from leadership's share acquisitions provides a minor offset but is not enough to significantly alter the overall outlook.

Positive Factors

Financial Stability

Omega Diagnostics' strong balance sheet with low leverage ensures financial stability, providing a solid foundation for long-term operations and potential growth opportunities.

Profitability

A healthy net profit margin reflects Omega Diagnostics' ability to generate profit from its operations, which is crucial for reinvestment and shareholder returns over the long term.

Product Demand

The sustained demand for diagnostic testing supports Omega Diagnostics' revenue streams, ensuring continued market relevance and potential for growth in the healthcare sector.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in maintaining sales momentum, which could impact Omega Diagnostics' ability to invest in growth initiatives and compete effectively.

Cash Flow Issues

Negative cash flow growth suggests difficulties in generating sufficient cash, potentially limiting Omega Diagnostics' operational flexibility and ability to fund future investments.

Operational Inefficiencies

Operational inefficiencies, as indicated by a negative EBIT margin, may hinder Omega Diagnostics' ability to optimize costs and improve profitability, affecting long-term competitiveness.

Omega Diagnostics Business Overview & Revenue Model

Company Description

Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the Foodprint name. It provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The company serves government, private hospitals, reference laboratories, nutritionists, naturopaths, and other healthcare professionals. Cambridge Nutritional Sciences plc operates in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc was founded in 1987 and is based in London, the United Kingdom.

How the Company Makes Money

Omega Diagnostics generates revenue through the sale of its diagnostic products, which are marketed to hospitals, laboratories, and healthcare providers. The company has established key revenue streams from the distribution of its allergy testing kits and infectious disease diagnostics, which are often sold directly to healthcare facilities or through third-party distributors. Additionally, Omega may benefit from partnerships with other companies in the healthcare and diagnostics sectors, which can provide access to new markets and enhance its product offerings. The ongoing demand for accurate diagnostic testing in the healthcare industry, particularly in light of emerging health challenges, plays a significant role in sustaining and growing its earnings.

Omega Diagnostics Financial Statement Overview

Summary

Omega Diagnostics presents a mixed financial picture. The income statement shows profitability but declining revenue and operational inefficiencies. The balance sheet is strong with low leverage and reasonable returns on equity, indicating financial stability. However, the cash flow statement highlights significant cash management challenges and potential liquidity risks.

Income Statement

Omega Diagnostics shows a mixed performance in its income statement. The company has a positive net profit margin of 18.80% in the latest year, indicating profitability. However, the revenue growth rate is negative at -7.18%, suggesting a decline in sales. The gross profit margin is healthy at 60.08%, but the EBIT margin is negative, reflecting operational challenges. Overall, the income statement reflects profitability but with declining revenue and operational inefficiencies.

Balance Sheet

The balance sheet of Omega Diagnostics is relatively strong with a low debt-to-equity ratio of 0.03, indicating low leverage and financial stability. The return on equity is 13.73%, showing a decent return for shareholders. The equity ratio is not explicitly calculated, but the low debt levels suggest a strong equity position. Overall, the balance sheet reflects financial stability with low leverage and reasonable returns on equity.

Cash Flow

Cash flow analysis reveals significant challenges for Omega Diagnostics. The free cash flow growth rate is negative at -125.27%, indicating deteriorating cash generation. The operating cash flow to net income ratio is low at 0.04, suggesting weak cash conversion. The free cash flow to net income ratio is negative, highlighting cash flow issues. Overall, the cash flow statement indicates significant cash management challenges and potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.06M	8.33M	9.77M	7.55M	8.54M	6.82M
Gross Profit	4.91M	5.00M	6.05M	3.17M	4.75M	4.00M
EBITDA	2.01M	2.20M	-73.00K	-2.65M	-382.00K	418.00K
Net Income	1.36M	1.57M	-328.00K	-3.86M	-11.33M	-2.10M
Balance Sheet
Total Assets	12.69M	13.80M	13.89M	14.40M	17.84M	29.55M
Cash, Cash Equivalents and Short-Term Investments	3.59M	4.87M	5.44M	5.12M	1.60M	5.83M
Total Debt	237.00K	349.00K	148.00K	74.00K	370.00K	2.84M
Total Liabilities	1.64M	2.39M	4.21M	4.45M	6.02M	6.16M
Stockholders Equity	11.05M	11.41M	9.68M	9.95M	11.82M	23.38M
Cash Flow
Free Cash Flow	-437.00K	-142.00K	548.00K	-3.31M	-4.71M	-5.24M
Operating Cash Flow	-166.00K	83.00K	607.00K	-3.15M	-3.23M	-2.42M
Investing Cash Flow	-482.00K	2.12M	-2.51M	5.18M	-493.00K	-2.83M
Financing Cash Flow	-233.00K	-251.00K	-265.00K	1.49M	-502.00K	11.07M

Omega Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Negative. The current price of 1.95 is below the 20-day moving average (MA) of 2.07, below the 50-day MA of 2.35, and below the 200-day MA of 2.97, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 5.06 is Positive, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CNSL.

Omega Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	77 Outperform	£199.42M	29.99	20.31%	3.40%	10.80%	1.75%
EKF	67 Neutral	£112.29M	19.11	8.71%	―	-1.43%	28.57%
RUA	62 Neutral	£7.60M	1,225.00	0.08%	―	87.72%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNSL	50 Neutral	£4.64M	3.42	13.26%	―	-10.20%	714.29%
FDBK	49 Neutral	£3.44M	-0.30	-105.98%	―	-25.05%	-5.74%

Omega Diagnostics Corporate Events

Cambridge Nutritional Sciences Leadership Increases Shareholdings

Cambridge Nutritional Sciences plc announced that Carolyn Rand, Non-Executive Chair, and Jeremy Millard, Non-Executive Director, have acquired additional shares in the company. Rand purchased 150,000 shares at an average price of 2.32 pence, while Millard acquired 168,776 shares at 2.37 pence each. These transactions reflect a vote of confidence in the company’s future prospects by its leadership, potentially impacting stakeholder perceptions and market positioning.

Cambridge Nutritional Sciences Reports Revenue Decline but Improves Gross Margin

Cambridge Nutritional Sciences reported a decrease in revenue for the first half of 2025, with sales dropping to £3.9 million from £4.1 million in the same period last year. Despite this, the company achieved an improved gross margin of 67.7% due to production efficiencies and a favorable product mix. The company has restructured its sales and marketing teams to focus on long-term growth, particularly in regions where sales have lagged, such as mainland Europe. While the company expects full-year sales to be lower than the previous year, it remains confident in its strategic objectives, supported by a strong cash position and ongoing investments in new initiatives.

Cambridge Nutritional Sciences to Announce Half Year Results and Host Investor Presentation

Cambridge Nutritional Sciences plc has announced it will release its Half Year results for the six months ended 30 September 2025 on 10 November 2025. The company will host a live online presentation for shareholders and potential investors on the same day to discuss the results, providing an opportunity for engagement and transparency with stakeholders.